Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24


Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S.

Cell Death Dis. 2017 Aug 31;8(8):e3029. doi: 10.1038/cddis.2017.406.


ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusing.

Crosbie PA, Crosbie EJ, Aspinall-O'Dea M, Walker M, Harrison R, Pernemalm M, Shah R, Joseph L, Booton R, Pierce A, Whetton AD.

BMJ Open Respir Res. 2016 Feb 17;3(1):e000114. doi: 10.1136/bmjresp-2015-000114. eCollection 2016.


Protein Z: A putative novel biomarker for early detection of ovarian cancer.

Russell MR, Walker MJ, Williamson AJ, Gentry-Maharaj A, Ryan A, Kalsi J, Skates S, D'Amato A, Dive C, Pernemalm M, Humphryes PC, Fourkala EO, Whetton AD, Menon U, Jacobs I, Graham RL.

Int J Cancer. 2016 Jun 15;138(12):2984-92. doi: 10.1002/ijc.30020. Epub 2016 Feb 19.


Proteomics Analysis Reveals Distinct Corona Composition on Magnetic Nanoparticles with Different Surface Coatings: Implications for Interactions with Primary Human Macrophages.

Vogt C, Pernemalm M, Kohonen P, Laurent S, Hultenby K, Vahter M, Lehtiö J, Toprak MS, Fadeel B.

PLoS One. 2015 Oct 7;10(10):e0129008. doi: 10.1371/journal.pone.0129008. eCollection 2015.


Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value.

Walker MJ, Zhou C, Backen A, Pernemalm M, Williamson AJ, Priest LJ, Koh P, Faivre-Finn C, Blackhall FH, Dive C, Whetton AD.

EBioMedicine. 2015 Jun 19;2(8):841-50. doi: 10.1016/j.ebiom.2015.06.013. eCollection 2015 Aug.


Identifying and Assessing Interesting Subgroups in a Heterogeneous Population.

Lee W, Alexeyenko A, Pernemalm M, Guegan J, Dessen P, Lazar V, Lehtiö J, Pawitan Y.

Biomed Res Int. 2015;2015:462549. doi: 10.1155/2015/462549. Epub 2015 Aug 3.


Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions.

Dinets A, Pernemalm M, Kjellin H, Sviatoha V, Sofiadis A, Juhlin CC, Zedenius J, Larsson C, Lehtiö J, Höög A.

PLoS One. 2015 May 15;10(5):e0126472. doi: 10.1371/journal.pone.0126472. eCollection 2015.


Molecular histology of lung cancer: from targets to treatments.

Wood SL, Pernemalm M, Crosbie PA, Whetton AD.

Cancer Treat Rev. 2015 Apr;41(4):361-75. doi: 10.1016/j.ctrv.2015.02.008. Epub 2015 Feb 20. Review.


Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.

Azimi A, Pernemalm M, Frostvik Stolt M, Hansson J, Lehtiö J, Egyházi Brage S, Hertzman Johansson C.

Br J Cancer. 2014 May 13;110(10):2489-95. doi: 10.1038/bjc.2014.169. Epub 2014 Apr 10.


Mass spectrometry-based plasma proteomics: state of the art and future outlook.

Pernemalm M, Lehtiö J.

Expert Rev Proteomics. 2014 Aug;11(4):431-48. doi: 10.1586/14789450.2014.901157. Epub 2014 Mar 24. Review.


The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets.

Wood SL, Pernemalm M, Crosbie PA, Whetton AD.

Cancer Treat Rev. 2014 May;40(4):558-66. doi: 10.1016/j.ctrv.2013.10.001. Epub 2013 Oct 15. Review.


Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism.

Pernemalm M, De Petris L, Branca RM, Forshed J, Kanter L, Soria JC, Girard P, Validire P, Pawitan Y, van den Oord J, Lazar V, Påhlman S, Lewensohn R, Lehtiö J.

J Proteome Res. 2013 Sep 6;12(9):3934-43. doi: 10.1021/pr4002096. Epub 2013 Aug 13.


Narrow-range peptide isoelectric focusing as peptide prefractionation method prior to tandem mass spectrometry analysis.

Pernemalm M.

Methods Mol Biol. 2013;1023:3-11. doi: 10.1007/978-1-4614-7209-4_1.


A novel prefractionation method combining protein and peptide isoelectric focusing in immobilized pH gradient strips.

Pernemalm M, Lehtiö J.

J Proteome Res. 2013 Feb 1;12(2):1014-9. doi: 10.1021/pr300817y. Epub 2012 Dec 24.


Network enrichment analysis: extension of gene-set enrichment analysis to gene networks.

Alexeyenko A, Lee W, Pernemalm M, Guegan J, Dessen P, Lazar V, Lehtiö J, Pawitan Y.

BMC Bioinformatics. 2012 Sep 11;13:226. doi: 10.1186/1471-2105-13-226.


Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ).

Forshed J, Johansson HJ, Pernemalm M, Branca RM, Sandberg A, Lehtiö J.

Mol Cell Proteomics. 2011 Oct;10(10):M111.010264. doi: 10.1074/mcp.M111.010264. Epub 2011 Jul 6.


A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants.

De Petris L, Pernemalm M, Elmberger G, Bergman P, Orre L, Lewensohn R, Lehtiö J.

Proteome Sci. 2010 Feb 26;8:9. doi: 10.1186/1477-5956-8-9.


Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion.

Pernemalm M, De Petris L, Eriksson H, Brandén E, Koyi H, Kanter L, Lewensohn R, Lehtiö J.

Proteomics. 2009 Jul;9(13):3414-24. doi: 10.1002/pmic.200800814.


Affinity prefractionation for MS-based plasma proteomics.

Pernemalm M, Lewensohn R, Lehtiö J.

Proteomics. 2009 Mar;9(6):1420-7. doi: 10.1002/pmic.200800377. Review.


Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.

De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.

Lung Cancer. 2009 Mar;63(3):410-7. doi: 10.1016/j.lungcan.2008.06.003. Epub 2008 Jul 11.


Supplemental Content

Loading ...
Support Center